Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ball, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ball, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 21-27
© 2003 The British Society for Antimicrobial Chemotherapy

Supplement

Adverse drug reactions: implications for the development of fluoroquinolones

Peter Ball*

School of Biomedical Sciences, University of St Andrews, St. Andrews, Fife, Scotland, UK

Abstract

Quinolone antibacterials, originally derived from anti-malarial compounds, have been developed through side-chain and nuclear manipulation, notably by piperazine and other mono- or bi-cyclic substitutions at the 7 position (giving anti-pseudomonal activity and greater anti-Gram-negative activity) and fluorination at various sites (giving increased anti-Gram-positive activity). The class has now been in clinical use for 40 years. Increased activity has not been without cost: for example, specific idiosyncratic reactions have consigned agents such as the 1-(2,4)-difluorophenyl compounds, such as temafloxacin (haemolytic uraemic syndrome) and trovafloxacin (hepatotoxic reactions), to restriction, suspension or withdrawal. Class adverse drug reactions (ADRs), variable in frequency and severity within the group, have significantly affected individual groups of compounds, such as the 8-chloro derivatives (Bay y 3118, clinafloxacin and sitafloxacin), which, whilst extremely potent, are also highly phototoxic and have largely been discarded.

Footnotes

* Correspondence address. 6 Gilchrist Row, St. Andrews, Fife KY16 8XU, Scotland. E-mail: Peterball1{at}aol.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
H.-S. Park, H.-J. Kim, M.-J. Seol, D.-R. Choi, E.-C. Choi, and J.-H. Kwak
In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2261 - 2264.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Tachibana, M. Tanaka, Y. Masubuchi, and T. Horie
ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., June 1, 2005; 33(6): 803 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Komp Lindgren, A. Karlsson, and D. Hughes
Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections
Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3222 - 3232.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.